Form 8-K - Current report:
SEC Accession No. 0001140361-25-035251
Filing Date
2025-09-17
Accepted
2025-09-17 16:15:50
Documents
15
Period of Report
2025-09-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20055707_form8k.htm   iXBRL 8-K 33125
2 EXHIBIT 10.1 ef20055707_ex10-1.htm EX-10.1 77418
3 EXHIBIT 10.2 ef20055707_ex10-2.htm EX-10.2 52544
7 logo1.jpg GRAPHIC 7399
  Complete submission text file 0001140361-25-035251.txt   336626

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rckt-20250911.xsd EX-101.SCH 3877
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rckt-20250911_lab.xml EX-101.LAB 21966
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rckt-20250911_pre.xml EX-101.PRE 16052
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20055707_form8k_htm.xml XML 4057
Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Filer) CIK: 0001281895 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36829 | Film No.: 251320189
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)